Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484093 · ClinicalTrials.gov registry record · Phase 1
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT01484093: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01484093 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01484093, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
Mantle cell lymphoma (MCL) is a rare and aggressive type of lymphoma, with only about 3,000 cases diagnosed per year. MCL is considered a difficult cancer to treat. This study is being done to better understand how to treat MCL.
Interventions
- OTHER R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2011-11-29 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484093
The ClinicalTrials.gov registry entry for NCT01484093 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR. is the first listed.
NCT01484093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484093 about?
NCT01484093 is a clinical study titled "Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma". Mantle cell lymphoma (MCL) is a rare and aggressive type of lymphoma, with only about 3,000 cases diagnosed per year. MCL is considered a difficult cancer to treat. This study is being done to better understand how to treat MCL.
What is the current status of trial NCT01484093?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2011-11-29. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT01484093?
The interventions under investigation include: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR. (OTHER).
Who is sponsoring clinical trial NCT01484093?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.